Cargando…

PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study

SIMPLE SUMMARY: Prostate-specific membrane antigen-direct radioligand therapy is a novel treatment for patients with castration-resistant prostate cancer. Yet, given the mode of action of PSMA-RLT, it is postulated that in early disease prostate cancer settings, e.g. hormone-sensitive, can also bene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banda, Amina, Privé, Bastiaan M., Allach, Youssra, Uijen, Maike J. M., Peters, Steffie M. B., Loeff, Cato C., Gotthardt, Martin, Muselaers, Constantijn H. J., Witjes, J. Alfred, van Oort, Inge M., Sedelaar, J. P. Michiel, Westdorp, Harm, Mehra, Niven, Khreish, Fadi, Ezziddin, Samer, Sabet, Amir, Kreissl, Michael C., Winkens, Thomas, Seifert, Philipp, Janssen, Marcel J. R., van Gemert, Willemijn A. M., Nagarajah, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818570/ https://www.ncbi.nlm.nih.gov/pubmed/36612293 http://dx.doi.org/10.3390/cancers15010297

Ejemplares similares

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation
por: Peters, Steffie M. B., et al.
Publicado: (2023)

Intra-therapeutic dosimetry of [(177)Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome
por: Peters, Steffie M. B., et al.
Publicado: (2021)

An Explorative Study of the Incidental High Renal Excretion of [(18)F]PSMA-1007 for Prostate Cancer PET/CT Imaging
por: Allach, Youssra, et al.
Publicado: (2022)

[(68)Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [(177)Lu]Lu-PSMA-617 treatment
por: Peters, Steffie M. B., et al.
Publicado: (2021)

Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
por: Privé, Bastiaan M., et al.
Publicado: (2021)

Value of Combined PET Imaging with [(18)F]FDG and [(68)Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [(177)Lu]Lu-PSMA-617 RLT
por: Khreish, Fadi, et al.
Publicado: (2021)

PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports
por: Uijen, M. J. M., et al.
Publicado: (2021)

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
por: Privé, Bastiaan M., et al.
Publicado: (2020)

RLT-S: A Web System for Record Linkage
por: Mamun, Abdullah-Al, et al.
Publicado: (2015)

Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies
por: Privé, Bastiaan M., et al.
Publicado: (2023)

[(89)Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates
por: Rosar, Florian, et al.
Publicado: (2022)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

Does PRRT with standard activities of (177)Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors
por: Sabet, Amir, et al.
Publicado: (2013)

Interactive range‐limit theory (iRLT): An extension for predicting range shifts
por: Sirén, Alexej P. K., et al.
Publicado: (2019)

177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)
por: Khreish, Fadi, et al.
Publicado: (2021)

Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE
por: Sabet, Amir, et al.
Publicado: (2021)

(68)Ga–Prostate-Specific Membrane Antigen-11–Avid Cardiac Metastases in a Patient With Adenoid Cystic Carcinoma, A Rare Presentation of a Rare Cancer
por: Uijen, Maike José Maria, et al.
Publicado: (2020)

Response Assessment and Prediction of Progression-Free Survival by (68)Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing (177)Lu-PSMA-617 Radioligand Therapy
por: Khreish, Fadi, et al.
Publicado: (2021)

Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review
por: Urso, Luca, et al.
Publicado: (2022)

Systemic Mastocytosis Treatment with Midostaurin: [(18)F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome
por: Burgard, Caroline, et al.
Publicado: (2022)

Head-to-Head Comparison of (68)Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients
por: Schilham, Melline G.M., et al.
Publicado: (2021)

Study on the Anticancer Effect of an Astragaloside- and Chlorogenic Acid-Containing Herbal Medicine (RLT-03) in Breast Cancer
por: Li, Yanchu, et al.
Publicado: (2020)

Electromyographic Response of the Abdominal Muscles and Stabilizers of the Trunk to Reflex Locomotion Therapy (RLT). A Preliminary Study
por: Pérez-Robledo, Fátima, et al.
Publicado: (2022)

Prostate-specific membrane antigen (PSMA)–ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer
por: Tateishi, Ukihide
Publicado: (2020)

Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer
por: Smits, Minke, et al.
Publicado: (2020)

Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of (177)Lu‐PSMA‐617 in prostate cancer patients
por: Siebinga, Hinke, et al.
Publicado: (2023)

Response to (225)Ac-PSMA-I&T after failure of long-term (177)Lu-PSMA RLT in mCRPC
por: Ilhan, Harun, et al.
Publicado: (2020)

PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [(68)Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression
por: Rosar, Florian, et al.
Publicado: (2022)

Strongly Radioiodine-Positive Pancreatic Adenocarcinoma Mimicking Metastasis of Differentiated Thyroid Cancer
por: Rosar, Florian, et al.
Publicado: (2022)

High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer
por: Westdorp, Harm, et al.
Publicado: (2020)

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
por: Westdorp, Harm, et al.
Publicado: (2019)

Tumor Sink Effect with Prostate-Specific Membrane Antigen-Targeted Theranostics in Patients with Metastatic Castration-Resistant Prostate Cancer: Intra-Individual Evaluations
por: Burgard, Caroline, et al.
Publicado: (2023)

Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
por: Rosar, Florian, et al.
Publicado: (2023)

(68)Ga-PSMA-PET/CT and Diffusion MRI Targeting for Cone-Beam CT-Guided Bone Biopsies of Castration-Resistant Prostate Cancer Patients
por: van Steenbergen, T. R. F., et al.
Publicado: (2019)

Molecular imaging and biochemical response assessment after a single cycle of [(225)Ac]Ac-PSMA-617/[(177)Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [(177)Lu]Lu-PSMA-617 monotherapy
por: Rosar, Florian, et al.
Publicado: (2021)

Renal Safety of [(177)Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
por: Rosar, Florian, et al.
Publicado: (2021)

Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [(177)Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure—Preliminary Evidence of Pilot Experience
por: Rosar, Florian, et al.
Publicado: (2022)

Detection Efficacy of (68)Ga-PSMA-11 PET/CT in Biochemical Recurrence of Prostate Cancer with Very Low PSA Levels: A 7-Year, Two-Center “Real-World” Experience
por: Burgard, Caroline, et al.
Publicado: (2023)

Neuron-specific enolase has potential value as a biomarker for [(18)F]FDG/[(68)Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients
por: Rosar, Florian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fdgj32iqb4j5kit1cjmf04t2fo